



## Injectafer® (ferric carboxymaltose) – New indication

- On November 19, 2021, the FDA approved American Regent's **Injectafer (ferric carboxymaltose)**, for the treatment of iron deficiency anemia (IDA) in adults and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron.
  - Injectafer was previously approved for this indication in adult patients only.
- Injectafer is also approved for the treatment of IDA in adult patients who have non-dialysis dependent chronic kidney disease.
- The use of Injectafer for the expanded indication is supported by evidence from adequate and well-controlled studies of Injectafer in adults with additional pharmacodynamic and safety data in pediatric patients aged 1 year and older.
- The most common adverse reactions ( $\geq 4\%$ ) with Injectafer use in pediatric patients were hypophosphatemia, injection site reactions, rash, headache, and vomiting.
- For pediatric patients weighing 50 kg or more, the recommended dosage of Injectafer is 750 mg intravenously (IV) in two doses separated by at least 7 days for a total cumulative dose of 1,500 mg of iron per course. For pediatric patients weighing less than 50 kg, the recommended dosage is Injectafer 15 mg/kg body weight IV in two doses separated by at least 7 days per course.
  - Refer to the Injectafer drug label for additional dosing in adults.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.